Alembic Pharmaceuticals NSE
784.45 00.00 (1.04%) 
To view real-time data of Alembic Pharmaceuticals and trade with industry first features, Login or Open Free Demat Account.
Financials:
Income Statement
as of March 2022
| Financial Year | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2018-19 | FY 2017-18 |
| All Expenditure (Cr) | 4,975.17 | 4,431.63 | 3,912.85 | 3,061.10 | 2,487.72 |
| Operating Profit (Cr) | 12.03 | 17.53 | 29.07 | 22.44 | 20.77 |
| EBIDTA (Cr) | 204.66 | 170.37 | 345.64 | 181.41 | 173.87 |
| Profit Before Tax (Cr) | 354.59 | 625.39 | 1,368.08 | 749.32 | 541.26 |
| Tax (Cr) | 12.60 | 104.45 | 253.32 | 156.75 | 120.36 |
| Net Income (Cr) | 5,576.71 | 5,404.72 | 5,674.35 | 4,036.33 | 3,179.90 |
| EPS (Cr) | 17.40 | 26.50 | 58.33 | 31.00 | 21.89 |
| DPS (Cr) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance Sheet
as of March 2022
Equities & Liabilities
| Financial Year | FY - | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
| Share Capital (Cr) | 39.31 | 39.31 | 39.31 | 37.70 | 37.70 |
| Reserves & Surplus (Cr) | 4,331.16 | 5,198.23 | 5,027.66 | 3,181.71 | 2,681.12 |
| Current Liabiltiies (Cr) | 1,067.28 | 1,269.25 | 1,157.59 | 1,051.36 | 1,001.35 |
| Other Liabilities (Cr) | 106.20 | 95.82 | 85.52 | 147.81 | 52.03 |
| Total Liabilities (Cr) | 5,198.69 | 6,050.47 | 5,736.10 | 5,085.75 | 3,898.50 |
Assets
| Financial Year | FY - | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
| Fixed Assets | 2,999.73 | 4,102.08 | 3,970.95 | 3,398.02 | 2,709.68 |
| Current Assets | 2,048.89 | 1,795.11 | 1,492.17 | 1,559.45 | 1,078.47 |
| Other Assets | 2,595.03 | 3,564.59 | 3,795.79 | 2,953.08 | 2,435.80 |
| Total Assets | 53.74 | 34.88 | 36.70 | 110.66 | 61.59 |
Cash Flows
as of March 2022
| Financial Year | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2018-19 | FY 2017-18 |
| Operating Activities (Cr) | 723.94 | 552.35 | 1,463.39 | 811.96 | 312.42 |
| Investing Activities (Cr) | -447.59 | -371.97 | -839.74 | -755.67 | -884.38 |
| Financing Activities (Cr) | -261.96 | -217.35 | -597.43 | 59.04 | 502.63 |
| Others (Cr) | 133.92 | 74.31 | -2.72 | -1.18 | -4.82 |
| Net Cash Flow (Cr) | 14.39 | -36.97 | 26.22 | 115.33 | -69.33 |
Frequently Asked Questions on Alembic Pharmaceuticals Share
Alembic Pharmaceuticals latest EBITDA stands at 204.66 for the financial year 2022-23, having previously been 204.662 during 2021-22. EBITDA is typically used to measure profitability instead of net income and other factors. You can view EBIDTA and other crucial financial data on Dhan Online Trading App and Web Trading Platform.
Alembic Pharmaceuticals EPS for the latest financial year stood at 17.40 compared to an EPS of 26.50 in the previous financial year. View EPS, P/E ratio, and other fundamental data to start investing in stocks on Dhan.
In the latest financial year gone by, Alembic Pharmaceuticals had a net income of 5,576.71 compared to a net income of 5,404.72 in the year before.
You can use Dhan App and Web to analyze financial statements and trade in
Alembic Pharmaceuticals Financial Statements Overview
Alembic Pharmaceuticals financial statements offers an overview of the company's Revenue, Income Statement, Balance Statement, Cash Flows and more. It helps to analyse the company's financial position and its revenue to profit trend. Alembic Pharmaceuticals reported a Net Income of Rs. 5,576.71 and an Operating Profit of Rs. 12.03 in the . The Total Liabilities stood at Rs. 5,198.69 in the last year. The Earning Per Share (EPS) and Dividend Per Share (DPS) stood at Rs. 17.40 and Rs. 0.00 respectively. While, analysing Financial Statements of a company is crucial, it is equally important to look at the Share Price, Stock Performance, Fundamental Analysis, Technicals and Similar Stocks Comparision. It gives a sense of whether the company is growing, stable or deteriorating.
